Recombinant Erythropoietin: Payment Options for Medicare
OTA-H-451
NTIS order #PB90-256124
Full Report ~897K
Front Matter ~23K
Table of Contents ~16K
Chapters
1: Summary and Policy Options ~217K
2: Clinical Significance of Recombinant erythropoietin ~120K
3: The Structure of the Marketplace ~91K
4: Medicare's Current Payment Policies ~52K
Appendices
A: Method of Study ~6K
B: Workshop Participants ~4K
C: Acknowledgements ~10K
D: Glossary of Terms and Acronyms ~20K
E: Method Used by the Office of the Inspector General to Estimate the Manufacturer¹s Costs of Recombinant erythropoietin ~19K
References ~347K
